Рынок лечения саркоидоза вырастет к 2036 году благодаря новым препаратам и росту осведомленности

The sarcoidosis market is expected to experience steady growth over the coming years, supported by increasing disease awareness, improvements in diagnosis, and the growing need for effective long-term treatment options. Additionally, the launch of emerging therapies such as KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), and others will further propel the market growth. LAS VEGAS, Sept. 8, 2026 /PRNewswire/ -- Recently published Sarcoidosis Market Insights report includes a comprehensive understanding of current treatment practices, sarcoidosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Sarcoidosis Market Summary The total sarcoidosis treatment market size is expected to grow positively by 2036 in the leading markets. The United States accounted for the largest sarcoidosis treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. Sarcoidosis is a rare disease, with an estimated 150,000-200,000 cases in the US each year and approximately 27,000 new cases diagnosed annually. Leading sarcoidosis companies, such as Kyorin Pharmaceutical, aTyr Pharma, Priovant Therapeutics, Molecure, Xentria, OrphAI Therapeutics, Quince Therapeutics, MindMaze Therapeutics, Foresee Pharmaceuticals, and others, are developing new sarcoidosis treatment drugs that can be available in the sarcoidosis market in the coming years. The promising sarcoidosis therapies in clinical trials include KRP-R120 (Efzofitimod), Brepocitinib, OATD-01, XTMAB-16, LAM-001, RLF-100, Aderamastat (FP-025), and others. Discover latest insights on sarcoidosis therapeutics market @ https://www.delveinsight.com/report-store/sarcoidosis-market Key Factors Driving the Growth of the Sarcoidosis Market Growing Prevalence of Sarcoidosis: An increasing number of diagnosed cases across major markets is expanding the addressable patient population. Improved disease surveillance and recognition of extrapulmonary manifestations are further contributing to higher diagnosis rates. Limitations of Existing Treatments: Corticosteroids remain a cornerstone of treatment, but their prolonged use can result in significant adverse effects. Concerns over steroid-related toxicity and inadequate responses in some patients are driving demand for alternative and steroid-sparing therapies. Expansion of Targeted and Biologic Therapies: Growing understanding of the immune pathways involved in sarcoidosis is accelerating the development of targeted treatments, including biologics and other immune-modulating therapies. These approaches could provide more effective disease control for patients with refractory disease. Growing Clinical Development Activity: Increasing investment from biotechnology and pharmaceutical companies has led to a more robust pipeline of sarcoidosis therapies including KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), LAM-001 (OrphAI Therapeutics/Quince Therapeutics), RLF-100 (MindMaze Therapeutics), Aderamastat (FP-025; Foresee Pharmaceuticals), and others. Multiple late-stage and mid-stage clinical programs are expected to generate important data over the coming years, supporting market expansion. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, efzofitimod is expected to achieve significant uptake following potential approval, supported by its novel immunomodulatory mechanism and ability to reduce corticosteroid dependence while preserving disease control. Its differentiated mechanism and favorable safety profile could position it as an attractive option for patients with chronic pulmonary sarcoidosis. Sarcoidosis Market Analysis The treatment landscape for sarcoidosis has progressed incrementally over the years; however, substantial unmet needs persist because of the limited number of therapies specifically developed for the disease. At present, Acthar Gel (repository corticotropin injection) remains the only FDA-approved treatment specifically indicated for symptomatic pulmonary sarcoidosis. Although corticosteroids and immunosuppressive therapies remain the cornerstone of management, their long-term use is associated with safety concerns, inconsistent treatment responses, and the risk of disease recurrence. These limitations have accelerated efforts to develop more targeted and disease-specific treatment strategies. Among the emerging therapies, efzofitimod has attracted significant attention because of its novel immunomodulatory mechanism and potential to reduce reliance on corticosteroids in patients with pulmonary sarcoidosis. Brepocitinib has shown promising clinical activity in cutaneous sarcoidosis and could provide a targeted option for addressing chronic inflammatory pathways implicated in disease progression. OATD-01 is evaluating a potentially first-in-class chitinase inhibition approach designed to influence granulomatous inflammation and fibrotic processes, while XTMAB-16 has progressed into mid-stage clinical development, with topline results anticipated to provide further insights into its therapeutic value. Collectively, these pipeline therapies employ diverse mechanisms of action and could broaden the treatment landscape beyond traditional immunosuppressive approaches. Overall, the sarcoidosis market across the 7MM is projected to expand steadily through 2036, driven by improvements in disease diagnosis and the increasing development of targeted treatment candidates. As these therapies advance through clinical development, agents offering steroid-sparing effects, enhanced safety, and potential disease-modifying benefits could substantially transform the treatment paradigm. This evolving pipeline may also unlock significant commercial opportunities within a market that currently has a relatively limited range of approved disease-specific treatment options. Sarcoidosis Competitive Landscape Some of the sarcoidosis drugs under development include KRP-R120 (Efzofitimod; Kyorin Pharmaceutical and aTyr Pharma), Brepocitinib (Priovant Therapeutics), OATD-01 (Molecure), XTMAB-16 (Xentria), LAM-001 (OrphAI Therapeutics/Quince Therapeutics), RLF-100 (MindMaze Therapeutics), Aderamastat (FP-025; Foresee Pharmaceuticals), and others. Kyorin Pharmaceutical and aTyr Pharma's Efzofitimod is an innovative biologic immunomodulator under clinical development for interstitial lung disease (ILD), a group of immune-mediated conditions characterized by lung inflammation and fibrosis, or permanent scarring. Derived from a tRNA synthetase, efzofitimod selectively targets activated myeloid cells through neuropilin-2, with the aim of resolving inflammation without causing broad immune suppression and potentially slowing or preventing fibrotic disease progression. The therapy is currently being evaluated in the Phase 2 EFZO-CONNECT study in patients with systemic sclerosis (SSc, also known as scleroderma)-associated ILD. In addition, aTyr has submitted a protocol to the FDA for a global Phase 3 trial evaluating efzofitimod in pulmonary sarcoidosis, a significant form of ILD. Given the limited treatment options available for these ILD subtypes, there remains a significant need for safer, more effective disease-modifying therapies that can improve patient outcomes. The US FDA has granted Orphan Drug Designation (ODD) to efzofitimod for the treatment of sarcoidosis, along with Fast Track Designation (FTD) for pulmonary sarcoidosis. In Europe, the European Commission has awarded efzofitimod Orphan Drug Designation for sarcoidosis following a positive recommendation from the EMA's Committee for Orphan Medicinal Products (COMP). In Japan, the Pharmaceutical and Medical Devices Agency (PMDA) has granted Kyorin Pharmaceutical Orphan Drug Designation for efzofitimod in the treatment of sarcoidosis. Priovant Therapeutics' Brepocitinib is an investigational oral dual TYK2/JAK1 inhibitor being developed for a range of autoimmune and inflammatory conditions, including cutaneous sarcoidosis. The therapy was assessed in the Phase 2 BEACON trial, a randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of oral brepocitinib in adults with cutaneous sarcoidosis. Following encouraging results from the Phase 2 BEACON study, Priovant intends to initiate a Phase 3 clinical trial of brepocitinib in cutaneous sarcoidosis in 2026. The anticipated launch of these emerging therapies are poised to transform the sarcoidosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the sarcoidosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Discover more about the pulmonary sarcoidosis market @ Sarcoidosis Therapeutics Clinical Trials Recent Developments in the Sarcoidosis Market In July 2026, aTyr Pharma, Inc. presented a subgroup analysis from the Phase 3 EFZO-FIT trial evaluating efzofitimod in pulmonary sarcoidosis, a significant type of interstitial lung disease, at the 2026 Congress of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG), held July 15-17, 2026, in Porto, Portugal. In May 2026, Xentria presented the latest update on XTMAB-16 in sarcoidosis. XTMAB-16 demonstrated a favorable safety and tolerability profile in patients with pulmonary sarcoidosis, without unexpected TNF-inhibitor class effects. Preliminary efficacy signals suggest that XTMAB-16 may facilitate corticosteroid reduction while preserving lung function and improving patient-reported outcomes. In May 2026, aTyr Pharma announced the path forward for efzofitimod in pulmonary sarcoidosis, following the receipt of the official meeting minutes from a Type C meeting with the UUS FDA. The purpose of the meeting was to review the results of the Phase III EFZO-FIT study and determine the next steps for the program in pulmonary sarcoidosis. In February 2026, Priovant Therapeutics announced positive results from the Phase II BEACON study evaluating brepocitinib in cutaneous sarcoidosis. The BEACON study is the first ever industry-sponsored placebo-controlled trial in the indication to read out positively. Sarcoidosis Epidemiology Segmentation The sarcoidosis epidemiology section provides insights into the historical and current sarcoidosis patient pool and forecasted trends for the leading markets. Sarcoidosis most commonly occurs in individuals between the ages of 20 and 60. While it was originally recognized in younger adults, current clinical observations show that over half of cases are now diagnosed in patients over 40 years old. The sarcoidosis treatment market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into: Total Diagnosed Prevalent Cases of Sarcoidosis Gender-specific Diagnosed Prevalent Cases of Sarcoidosis Age-specific Diagnosed Prevalent Cases of Sarcoidosis Total Treated Cases of Sarcoidosis Sarcoidosis Market Report Metrics | Details Study Period | 2022-2036 Coverage | 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Sarcoidosis Epidemiology Segmentation | Total Diagnosed Prevalent Cases of Sarcoidosis, Gender-specific Diagnosed Prevalent Cases of Sarcoidosis, Age-specific Diagnosed Prevalent Cases of Sarcoidosis, and Total Treated Cases of Sarcoidosis Key Sarcoidosis Companies | Kyorin Pharmaceutical, aTyr Pharma, Priovant Therapeutics, Molecure, Xentria, OrphAI Therapeutics, Quince Therapeutics, MindMaze Therapeutics, Foresee Pharmaceuticals, Mallinckrodt Pharmaceuticals, and others Key Sarcoidosis Therapies | KRP-R120 (Efzofitimod), Brepocitinib, OATD-01, XTMAB-16, LAM-001, RLF-100, Aderamastat (FP-025), Acthar Gel, and others Scope of the Sarcoidosis Market Report Sarcoidosis Patient Population Forecast Sarcoidosis Therapeutics Market Size Sarcoidosis Pipeline Analysis Sarcoidosis Market Size and Trends Sarcoidosis Market Opportunity Sarcoidosis Market Unmet Needs KOL's Views on Sarcoidosis Sarcoidosis Market Access and Reimbursement Download the report to understand the sarcoidosis drug market @ Sarcoidosis Drugs Table of Contents 1 | Sarcoidosis Market Key Insights 2 | Sarcoidosis Market Report Introduction 3 | Executive Summary 4 | Key Events 5 | Epidemiology and Market Methodology of Sarcoidosis 6 | Sarcoidosis Market Overview at a Glance 6.1 | Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA]) 6.2 | Market Share of Sarcoidosis By Therapies (%) in the 7MM in 2025 6.3 | Market Share of Sarcoidosis By Therapies (%) in the 7MM in 2036 7 | Disease Background And Overview of Sarcoidosis 7.1 | Introduction 7.2 | Causes 7.3 | Signs And Symptoms 7.4 | Diagnosis 7.5 | Treatment and Management 8 | Epidemiology and Patient Population of Sarcoidosis 8.1 | Key Findings 8.2 | Assumption and Rationale 8.3 | Total Prevalent Cases of Sarcoidosis in the 7MM 8.4 | The United States 8.4.1 | Total Diagnosed Prevalent Cases of Sarcoidosis in the United States 8.4.2 | Gender-specific Diagnosed Prevalent Cases of Sarcoidosis in the United States 8.4.3 | Age-specific Diagnosed Prevalent Cases of Sarcoidosis in the United States 8.4.4 | Total Treated Cases of Sarcoidosis in the United States 8.5 | EU4 and the UK 8.6 | Japan 9 | Patient Journey of Sarcoidosis 11 | Emerging Sarcoidosis Therapies 11.1 | Emerging Competitive Landscape of Sarcoidosis 11.2 | KRP-R120 (Efzofitimod): Kyorin Pharmaceutical and aTyr Pharma 11.2.1 | Product Description 11.2.2 | Other Developmental Activities 11.2.3 | Clinical Development 11.2.3.1 | Clinical Trial Information 11.2.4 | Safety and Efficacy 11.2.5 | Analyst Views 11.3 | Brepocitinib: Priovant Therapeutics 12 | Sarcoidosis Market: Seven Major Market Analysis 12.1 | Key Findings 12.2 | Market Outlook of Sarcoidosis 12.3 | Conjoint Analysis of Sarcoidosis 12.4 | Key Sarcoidosis Market Forecast Assumptions 12.5 | Total Market Size of Sarcoidosis in the 7MM 12.6 | The United States Sarcoidosis Market 12.6.1 | Total Market Size of Sarcoidosis in the United States 12.6.2 | Market Size of Sarcoidosis by Therapies in the United States 12.7 | EU4 and the UK Sarcoidosis Market 12.8 | Japan Sarcoidosis Market 13 | Unmet Needs of Sarcoidosis 14 | SWOT Analysis of Sarcoidosis 15 | KOL Views of Sarcoidosis 15.1 | Expert/KOL Interview Highlights 16 | Market Access and Reimbursement of Sarcoidosis 16.1 | The US 16.2 | In EU4 and the UK 16.3 | Japan 16.4 | Summary and Comparison of Market accesess and Pricing Policy Developments in 2025 16.5 | Market Access and Reimbursement of Sarcoidosis Therapies 17 | Bibliography 18 | Sarcoidosis Market Report Methodology Related Reports Sarcoidosis Clinical Trial Analysis Sarcoidosis Pipeline - 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key sarcoidosis companies, including Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, United Therapeutics Corporation, and others. Pulmonary Sarcoidosis Market Pulmonary Sarcoidosis Market Insights, Epidemiology, and Market Forecast - 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary sarcoidosis companies, including Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others. Interstitial Lung Disease Market Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast - 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ILD companies including GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol-Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor Biomedicines, Avalyn Pharma, United Therapeutics, Boehringer Ingelheim, Roche, and others. Systemic Sclerosis Market Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic sclerosis companies including Genentech, Kyowa Kirin, GSK, AstraZeneca, Amgen (Horizon Therapeutics), Mitsubishi Tanabe Pharma, Roche (Genentech), Kiniksa Pharmaceuticals, Boehringer Ingelheim, aTyr Pharma, Kyorin Pharmaceutical, Cumberland Pharmaceuticals, and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur [email protected] +14699457679 www.delveinsight.com View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sarcoidosis-market-forecast-emerging-therapies-and-increasing-disease-awareness-to-drive-expansion-by-2036--delveinsight-302871901.html KI braucht Strom Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke. Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation. Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten. In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen. Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!